✦ LIBER ✦

Abciximab: Cost-effective survival advantage in clinical trials and clinical practice

✍ Scribed by John J. Young; Dean J. Kereiakes

Book ID: 117842300
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 125 KB
Volume: 140
Category: Article
ISSN: 1097-6744
DOI: 10.1067/mhj.2000.111613

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Abciximab provides cost-effective surviv

Abciximab provides cost-effective survival advantage in high-volume interventional practice

✍ Dean J. Kereiakes; Robert L. Obenchain; Beth L. Barber; Andrew Smith; Mark McDon 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 129 KB

Cost Efficacy of Platelet Glycoprotein I

Cost Efficacy of Platelet Glycoprotein IIb/IIIa Antagonists in Clinical Trials and Clinical Practice

✍ JOHN J. YOUNG; DEAN J. KEREIAKES 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 580 KB

Cost-effectiveness analysis in clinical

Cost-effectiveness analysis in clinical trials

✍ Yick-Kwong Chan; Anne P. Cross; Gerald L. Wolf 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 85 KB

Cost-effectiveness analysis and clinical

Cost-effectiveness analysis and clinical practice

✍ Thomas S. Rector; Gary S. Francis 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 158 KB

Rufinamide: pharmacology, clinical trial

Rufinamide: pharmacology, clinical trials, and role in clinical practice

✍ A CHENG-HAKIMIAN; G. D. ANDERSON; J. W. MILLER 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB

Cost-effectiveness and lung cancer clini

Cost-effectiveness and lung cancer clinical trials

✍ Wei Du; Jaxk H. Reeves; Shirish Gadgeel; Judith Abrams; William P. Peters 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

## Abstract ## BACKGROUND Lung cancer is the leading cause of cancer death in the U.S., with an estimated annual economic burden of $5 billion. Clinical trials offer innovative therapeutic options with potentially better outcomes, but their effects on health care costs are disputed. ## METHODS T